Back to Search
Start Over
Gilead announces Phase 3 PURPOSE 1 trial met key efficiency endpoints
- Source :
- The Fly. June 20, 2024
- Publication Year :
- 2024
-
Abstract
- Gilead Sciences announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.798398414